Atlas Venture Opportunity Fund I, L.P.
CIK 1759241 · last filed 2022-11-01
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$762.12M
Companies
6
Total Filings
74
Lifetime Open-Market Net
-$54.65M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| KYMR | 10%+ Owner | 6,784,648 | $112.26 | $761.64M | -$52.41M | 1 | 2022-11-01 |
| Day One Biopharmaceuticals, Inc. (DAWN) Delisted | 10%+ Owner | 793,116 | $21.53 | $17.08M | $0 | 1 | 2022-07-06 |
| XLO | 10%+ Owner | 52,567 | $8.95 | $470.5K | $6.00M | 1 | 2021-10-26 |
| Generation Bio Co. (GBIO) Delisted | 10%+ Owner | 711,194 | $5.34 | $3.80M | -$8.24M | 1 | 2021-09-29 |
| ImageneBio, Inc. (IKNA) Delisted | 10%+ Owner | 241,801 | $17.16 | $4.15M | $0 | 1 | 2021-04-01 |
| Akero Therapeutics, Inc. (AKRO) Delisted | 10%+ Owner | 404,079 | $54.65 | $22.08M | $0 | 2 | 2020-02-10 |
Recent Filings · Page 7 of 8
74 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2024-02-28 | DYN | Notice (144) | −25,000 | -$615.0K | EDGAR |
| 2024-02-23 | DYN | Notice (144) | −100,000 | -$2.24M | EDGAR |
| 2024-02-23 | DYN | Notice (144) | −100,000 | -$2.24M | EDGAR |
| 2024-01-23 | IRON | Notice (144) | −82,500 | -$5.63M | EDGAR |
| 2024-01-10 | IRON | Notice (144) | −20,000 | -$1.29M | EDGAR |
| 2023-12-12 | IRON | Notice (144) | −100,000 | -$6.10M | EDGAR |
| 2023-08-15 | IRON | Notice (144) | −72,931 | -$3.82M | EDGAR |
| 2022-11-01 | KYMR | Sell (S) | −1,732,212 | -$52.41M | EDGAR |
| 2022-07-06 | Day One Biopharmaceuticals, Inc. (DAWN) Delisted | Other (J) | −198,280 | $0 | EDGAR |
| 2021-10-26 | XLO | Mixed | +5,466,058 | $6.00M | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.